Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALM009
- Development stage
- Unknown
- Lead developer
- Almatica Pharma
- Modality
- Small Molecules
01
Overview
ALM009 is a clinical-stage drug candidate developed by Almatica Pharma, a subsidiary of Alvogen, targeting central nervous system (CNS) disorders. Specifically indicated for the treatment of depression and anxiety, the candidate is currently in Phase 2 development. Almatica Pharma focuses on identifying and developing high-value specialty branded products, often involving optimized formulations or new indications for established therapeutic classes. However, the specific chemical identity, molecular target, and pharmacological profile of ALM009 remain proprietary and are not disclosed in the company's public pipeline documentation.
Beyond the preview
Go deeper on ALM009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALM009.